Price
$5.17
Decreased by -5.31%
Dollar Volume
4.42 M
ADR%
7.18
Earnings Report Date (estimate)
Feb 27, 23 (-0.51)
Market Cap.
490.52 M
Shares Float
71.81 M
Shares Outstanding
94.88 M
Beta
0.77
Price / Earnings
-1.42
BPR
27.12
20D Range
3.40 5.54
50D Range
2.83 5.54
200D Range
2.83 9.34
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.82
Increased by +8.89%
-0.78
Decreased by -5.13%
Aug 8, 22 0.18
Increased by +119.78%
-0.93
Increased by +119.35%
May 5, 22 -0.87
Decreased by -1.16%
-0.98
Increased by +11.22%
Feb 28, 22 -0.96
Decreased by -1.05%
-0.69
Decreased by -39.13%
Nov 4, 21 -0.90
Increased by +2.17%
-0.94
Increased by +4.26%
Aug 9, 21 -0.91
Increased by +20.18%
-0.89
Decreased by -2.25%
May 4, 21 -0.86
Increased by +28.33%
-0.92
Increased by +6.52%
Mar 1, 21 -0.95
Increased by +30.15%
-0.74
Decreased by -28.38%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 4.46 M
Decreased by -16.96%
-84.09 M
Increased by +0.68%
Decreased by -1.89 K%
Decreased by -19.62%
Jun 30, 22 51.58 M
Increased by +1.23 K%
18.47 M
Increased by +122.04%
Increased by +35.80%
Increased by +101.65%
Mar 31, 22 7.31 M
Increased by +105.91%
-88.11 M
Decreased by -12.47%
Decreased by -1.20 K%
Increased by +45.38%
Dec 31, 21 7.55 M
Increased by +N/A%
-93.35 M
Decreased by -14.81%
Decreased by -1.24 K%
Decreased by N/A%
Sep 30, 21 5.37 M
Increased by +N/A%
-84.66 M
Decreased by -13.88%
Decreased by -1.58 K%
Decreased by N/A%
Jun 30, 21 3.87 M
Increased by +N/A%
-83.79 M
Decreased by -8.18%
Decreased by -2.17 K%
Decreased by N/A%
Mar 31, 21 3.55 M
Increased by +N/A%
-78.33 M
Decreased by -6.57%
Decreased by -2.21 K%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-81.31 M
Decreased by -3.58%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.